BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models at Society of Biological Psychiatry 64rd Annual Scientific Convention & Meeting and Provides EAGLE Phase 2b Update


  • The ability of BL-1020 to improve episodic memory deficits suggests potential for the treatment of cognitive deficits in schizophrenia.
     
  • EAGLE Phase 2b update - Independent Safety Monitoring Board reviews safety data of first 200 patients
     

JERUSALEM--(BUSINESS WIRE)--May 18, 2009 - BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada, May 14-16, 2009. Recent data demonstrate that BL-1020 can repair chronic cognitive deficits in animal models, potentially via enhanced dopamine release in the pre-frontal cortex. Dr. Jo Neill, Professor of Psychopharmacology, at the School of Pharmacy, University of Bradford in UK, will present the findings.

”We are pleased to present these data at this important psychiatric conference. The potential of improving cognition addresses the unmet medical need in schizophrenia and supports our target product profile of developing a highly efficacious antipsychotic without compliance limiting extrapyramidal or metabolic side effects with the potential to improve cognition,” commented Morris C. Laster, MD, chief executive officer of BioLineRx. “We believe that the compound holds great promise for the treatment of schizophrenia, and are pleased to report that the ISMB has reviewed the safety data of the first 200 patients who completed the 6 week trial and did not report any safety concerns related to the trial. We are eagerly awaiting the results of our phase IIb EAGLE trial expected in Q3 of 2009.”

About BL-1020

BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. Previous clinical trials have shown that BL-1020 is an effective antipsychotic and that it is associated with minimal side effects that reduce patient compliance with current treatment regimens. Phase IIa trial results have shown the efficacy and tolerability of BL-1020.

We obtained a worldwide exclusive license for BL-1020 from Bar-Ilan Research and Development Company Ltd. and Ramot at Tel Aviv University Ltd. BL-1020 was invented by Prof. Abraham Nudelman (department of Chemistry, Bar-Ilan University), Dr. Ada Rephaeli, Prof. Abraham Weizman and Dr. Irit Gil-Ad (Faculty of Medicine, Tel-Aviv University).

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx seeks to enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.

Contact: BioLineRx Ltd.
Morris C. Laster, 972-2-5489100
CEO
morrisl@BioLineRx.com

Posted: May 2009

View comments

Hide
(web2)